Immunological detection of minimal residual disease in acute lymphoblastic leukemia

Onkologie

Volumn 24, Issue 5, 2001, Pages 442-448

  Dworzak, M N ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Flow cytometry; Lymphoblastic leukemia; Residual disease

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD99 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HERMES ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CANCER CELL; CANCER DIAGNOSIS; CELL DIFFERENTIATION; COST BENEFIT ANALYSIS; DIAGNOSTIC VALUE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGICAL MONITORING; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; QUANTITATIVE ASSAY; REVIEW; TECHNIQUE; TREATMENT OUTCOME;

B-LYMPHOCYTES; EPITOPES, B-LYMPHOCYTE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 0034755994     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055124     Document Type: Review

References (65)

1. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance
2. New definition of remission in childhood acute lymphoblastic leukemia
3. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)
4. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia
5. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
6. Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the Children's Cancer Group
7. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review
8. Acute lymphoblastic leukemia in children
9. The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification of antigen-receptor gene sequences
10. Detection of minimal residual disease in acute leukemia by flow cytometry
11. Immunophenotypical detection of minimal residual disease in acute leukemia
12. Clinical applicability of the evaluation of minimal residual disease in acute leukemia
13. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual in childhood acute lymphoblastic leukemia
14. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
15. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
16. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
17. Terminal transferase-positive human bone marrow cells exhibit the anti-genic phenotype of common acute lymphoblastic leukemia
18. Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected anti-body combinations
19. Analysis of the clinical and biological significance oflymphoidphenotypesin acute leukemia
20. B cell origin of non-T cell acute lymphoblastic leukemia - A model for discrete stages of neoplastic and normal pre-B cell differentiation
21. Monoclonal antibodies specific totheacute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: Characterization and diagnostic utility
22. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23
23. Human homologue of the rat chondroitin sulfate proteoglycan NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19) (q23;p13) and MLL gene rearrangements
24. A novel monoclonal antibody, KOR-SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukemia cells with high sensitivity
25. The KOR-SA3544 anti-gen predominantly expressed on the surface of Philadelphia chromosome-positive acute lymphoblastic leukemia cells is nonspecific cross-reacting antigen-50/90 (CD66c) and invariably expressed in cytoplasm of human leukemia cells
26. Phenotypic similarities and differences between CALLA-positive acute lymphoblastic leukemia cells and normal marrow CALLA-positve B cell precursors
27. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia
28. The immunologic detection of minimal residual disease in acute leukemia
29. Significance of aberrant immunophenotypes in childhood acute lymphoid leukemia
30. Flow cytometric determination of atypical anti-gen expression in acute leukemia for the study of minimal residual disease
31. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction
32. Acute lymphoblastic leukemia (ALL): Detection of minimal residual disease (MRD) at flow cytometry
33. Coexpression of p165 myeloid surface antigen and terminal deoxynucleotidyl transferase: A comparison of acute myeloid leukaemia and normal bone marrow cells
34. Double marker analysis for terminal deoxynucleotidyl transferase and myeloid antigens in acute nonlymphocytic leukemia patients and healthy subjects
35. Distribution of surface-membrane molecules on bone marrow and cord blood CD34+ hematopoietic cells
36. Regulation of human B-cell ontogeny
37. Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells
38. Phenotypic heterogeneity of TDT+ cells in the blood and bone marrow: Implications for surveillance of residual leukemia
39. Interleukin-7 induces the proliferation of normal human B-cell precursors
40. Multi-parameter phenotype mapping of normal and post- chemotherapy B lymphopoiesis in pediatric bone marrow
41. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny
42. Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens
43. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: Implications for minimal residual disease detection
44. CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis
45. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia
46. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
47. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: Detection in remission marrow predicts outcome
48. Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features
49. Leukemia-associated changes identified by quantitative flow cytometry: I. CD10 expression
50. Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors
51. Differential expression of CD3 and CD7 in T-cell malignancies: A quantitative study by flow cytometry
52. Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations
53. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myelo-blasts after chemotherapy and bone marrow transplantation
54. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: A study of five cases controlled by genetic methods
55. Flow cytometric analysis of normal B cell differentiation. A frame of reference for the detection of minimal residual disease in precursor-B-ALL
56. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: Implications for residual disease detection
57. BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subset in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)
58. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry
59. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukemia
60. Detection of minimal residual acute lymphoblastic leukemia by immunological marker analysis: Possibilities and limitations
61. Detection of leukaemic lymphoblasts in CSF by immunofluorescence for terminal transferase
62. Terminal deoxynucleotidyl transferase (TdT)-positive cells in cerebrospinal fluid and development of overt CNS leukemia: A 5-year follow-up study in 113 children with a TdT-positive leukemia or non-Hodgkin's lymphoma
63. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: Method and significance
64. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: Implications for monitoring of minimal residual disease
65. Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy